Armata Pharmaceuticals, Inc. ARMP

ARMP Company Overview

Armata Pharmaceuticals, Inc. is a U.S.-based biotechnology company focused on the development of bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. The company operates within the biotechnology and infectious disease sectors, with a primary emphasis on precision-targeted phage therapy as an alternative or complement to conventional antibiotics. Armata’s core product candidates are designed to address serious infections caused by pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, including strains associated with chronic and drug-resistant conditions.

The company’s primary revenue activity has historically consisted of collaboration agreements, research funding, and capital financing rather than commercial product sales, as its therapies remain in clinical development stages. Armata originated through the merger of C3J Therapeutics and AmpliPhi Biosciences Corporation, with the combined entity adopting the Armata Pharmaceuticals name in 2019. The company has positioned itself as one of the few publicly traded biotechnology firms dedicated primarily to bacteriophage therapeutics, leveraging a proprietary phage library and manufacturing capabilities intended to support personalized and standardized phage-based treatments.